Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis

Cancer Science

Volumn 104, Issue 4, 2013, Pages 508-515

  Fu, Jia ^a   Qiu, Huijuan ^a   Cai, Muyan ^a   Pan, Yinghua ^b   Cao, Yun ^a   Liu, Lili ^a   Yun, Jingping ^a   Zhang, Chris Zhiyi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CYCLIN F; CYCLINE; MESSENGER RNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CYCLINS; DOWN-REGULATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875606355     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12100     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ferlay JSH, Bray F, Forman D, Mathers CD, Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. [Cited 17 Aug 2010.] Available from: http://globocaniarcfr 2010 Last accessed 8/17/2010.
3. Erichsen R, Jepsen P, Jacobsen J, Norgaard M, Vilstrup H, Sorensen HT. Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985-2004. Eur J Gastroenterol Hepatol 2008; 20: 104-10.
4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-16.
5. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 3030-44.
6. Wong DK, Huang FY, Lai CL et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829-36.
7. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol 2012; 56: 267-75.
8. Breuhahn K, Gores G, Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology 2011; 53: 2112-21.
9. Suryadinata R, Sadowski M, Sarcevic B. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci Rep 2010; 30: 243-55.
10. Arellano M, Moreno S. Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol 1997; 29: 559-73.
11. Bai C, Richman R, Elledge SJ. Human cyclin F. EMBO J 1994; 13: 6087-98.
12. Fung TK, Siu WY, Yam CH, Lau A, Poon RY. Cyclin F is degraded during G2-M by mechanisms fundamentally different from other cyclins. J Biol Chem 2002; 277: 35140-9.
13. Kong M, Barnes EA, Ollendorff V, Donoghue DJ. Cyclin F regulates the nuclear localization of cyclin B1 through a cyclin-cyclin interaction. EMBO J 2000; 19: 1378-88.
14. D'Angiolella V, Donato V, Vijayakumar S et al. SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 2010; 466: 138-42.
15. Emanuele MJ, Elia AE, Xu Q et al. Global identification of modular cullin-RING ligase substrates. Cell 2011; 147: 459-74.
16. D'Angiolella V, Donato V, Forrester FM et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 2012; 149: 1023-34.
17. Liu L, Zhang CZ, Cai M, Fu J, Chen GG, Yun J. Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS ONE 2012; 7: e41293.
18. Cai MY, Zhang B, He WP et al. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 2010; 101: 1543-9.
19. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007; 60: 1112-16.
20. Dementyeva E, Nemec P, Kryukov F et al. Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma. Leuk Res 2010; 34: 1007-11.
21. Shinmura K, Iwaizumi M, Igarashi H et al. Induction of centrosome amplification and chromosome instability in p53-deficient lung cancer cells exposed to benzo[a]pyrene diol epoxide (B[a]PDE). J Pathol 2008; 216: 365-74.
22. Aaltonen K, Amini RM, Heikkila P et al. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer 2009; 100: 1055-60.
23. Aaltonen K, Amini RM, Landberg G et al. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat 2009; 113: 75-82.
24. Scaltriti M, Eichhorn PJ, Cortes J et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 2011; 108: 3761-6.
25. Leon J, Ferrandiz N, Acosta JC, Delgado MD. Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis? Cell Cycle 2009; 8: 1148-57.
26. Wang J, Yang Y, Xia HH et al. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. Gastroenterology 2007; 132: 1066-76.
27. Movsesyan V, Whalin M, Shibutani M, Katagiri Y, Broude E, Guroff G. Down-regulation of cyclin F levels during nerve growth factor-induced differentiation of PC12 cells. Exp Cell Res 1996; 227: 203-7.
28. Pascreau G, Eckerdt F, Churchill ME, Maller JL. Discovery of a distinct domain in cyclin A sufficient for centrosomal localization independently of Cdk binding. Proc Natl Acad Sci U S A 2010; 107: 2932-7.
29. Fidalgo daSilva E, Ansari SB, Maimaiti J et al. The tumor suppressor tuberin regulates mitotic onset through the cellular localization of cyclin B1. Cell Cycle 2011; 10: 3129-39.
30. Weng L, Du J, Zhou Q et al. Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection. Mol Cancer 2012; 11: 39.
31. Caldon CE, Sergio CM, Kang J et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 2012; 11: 1488-99.
32. Cui X, Yu L, Wang Y et al. The relationship between cyclin G1 and survival in patients treated surgically for HCC. Hepatogastroenterology 2012; 60. doi: 10.5754/hge12549 [Epub ahead of print].
33. Akli S, Zhang XQ, Bondaruk J et al. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle 2012; 11: 1468-76.
34. Ogino S, Nosho K, Irahara N et al. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 2009; 15: 4431-8.
35. Che Y, Ye F, Xu R et al. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol 2012; 180: 1798-807.